ScripLexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar
Pink SheetMore than five years after releasing its draft guidance on clinical trials with multiple endpoints, the US Food and Drug Administration has put out a final version of that guidance, with an eye toward
ScripMore than five years after releasing its draft guidance on clinical trials with multiple endpoints, the US Food and Drug Administration has put out a final version of that guidance, with an eye toward
Pink SheetOne of the most interesting regulatory events last week is one that didn’t happen: Bristol Myers Squibb Company pulled an sBLA for Reblozyl ahead of its user fee goal date, avoiding a complete respo